Nintedanib for Systemic Sclerosis–Associated Interstitial Lung Disease

Oliver Distler, Kristin B. Highland, Martina Gahlemann, +12

New England Journal of Medicine

Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database

Anna‐Maria Hoffmann‐Vold, Yannick Allanore, Margarida Alves, +13

Annals of the Rheumatic Diseases

Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial

James R. Seibold, Toby M. Maher, Kristin B. Highland, +9

Annals of the Rheumatic Diseases

Effect of Nintedanib on Lung Function in Patients With Systemic Sclerosis−Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double‐Blind, Placebo‐Controlled Trial

Toby M. Maher, Maureen D. Mayes, Michael Kreuter, +8

Arthritis & Rheumatology

Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: data from SENSCIS-ON

Yannick Allanore, Madelon C Vonk, Oliver Distler, +8

Annals of the Rheumatic Diseases

Nintedanib in Patients With Systemic Sclerosis–Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score

Masataka Kuwana, Yannick Allanore, Christopher P. Denton, +11

Arthritis & Rheumatology

Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial

Christopher P. Denton, Nicole Goh, Stephen M. Humphries, +8

Lara D. Veeken

Dyspnoea and cough in patients with systemic sclerosis–associated interstitial lung disease in the SENSCIS trial

Elizabeth R. Volkmann, Michael Kreuter, Anna‐Maria Hoffmann‐Vold, +9

Lara D. Veeken

Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression

Dinesh Khanna, Toby M. Maher, Elizabeth R. Volkmann, +10

RMD Open

Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study

Qiang Li, Laura Wallace, Padmaja Patnaik, +6

Lara D. Veeken